Recorded at AIHce EXP 2023
Surveillance for environmental contamination of antineoplastic drugs has been recommended by authoritative bodies such as the United States Pharmacopeia (USP) and the National Association of Pharmacy Regulatory Authorities (NAPRA). There is general acceptance that surveillance is best accomplished using surface wipe sampling. However, sampling strategies that align with surveillance objectives are undefined. Wipe sampling surveillance presents a number of challenges that are different from the typical air sampling scenario, such as: a) area versus personal monitoring, b) lack of OEL's, and c) there is a dermal hazard, not an inhalation one. Presenters will review a surveillance study of nine cancer-care centers, generating over 20,000 individual exposure measurements. This data was used to evaluate different sampling strategies, by a series of mathematical simulations. This education session, will present: 1) a surface wipe sampling strategy for clinical care settings, 2) recommendations on the number of drugs that should be sampled, 3) types of surfaces, 4) assessment criteria for comparison of results, 5 the data that was used to develop these sampling strategies, and 6) the benefits and limitations of this approach.
Upon completion of the session, the participant will be able to:
• Describe the challenges of surface sampling for antineoplastic drugs.
• Develop a surface sampling strategy for antineoplastic drugs in a clinical care setting.
• Analyze and interpret results from a surface sampling program.
• React to ongoing limitations and challenges in a surface surveillance program.
Hugh Davies, PhD, CIH
Susan Arnold, PhD, CIH, FAIHA